Insurances & Business

Sirtex Supports the Fourth Annual Clinical Symposium on Liver-Directed Microsphere Therapy Dedicated to Advancing Treatments for Patients with Inoperable Metastatic Liver Cancer (Business Wire)

Business | Sources: Yahoo

Similar/Related/News:

• Breast Cancer Treatment Disparities Between Black, White Women In Georgia Exist Despite Health Insurance Status, Study Finds
Black women in Georgia newly diagnosed with breast cancer are less likely to receive adequate health care treatment than whites even when they have he...
• Should Patients Be Allowed To Pay Top-up Fees To Acquire Certain Treatments?
Should patients be allowed to purchase the treatment they want? UKIn the UK, some believe that patients should be allowed to purchase anytreatments th...
• Pfizer Warns of Lung Cancer With Inhaled Insulin
NEW YORK (Reuters) - Pfizer Inc <PFE.N> and Nektar Therapeutics <NKTR.O> said on Wednesday clinical trials of the inhaled insulin Exub...
• ImClone Shares Rise on Pipeline Advance (AP)
Shares of ImClone Systems Inc. rose Thursday following the biotechnology company's announcement it will move a head-and-neck cancer drug candidate int...
• Business in the Burbs: Putnam businesses to display products, services
Local businesses in Putnam County will be showcasing their products and services next week at the Fourth Annual Shop Putnam Business and Home Expo....
• Healthcare Activists Plan June 19th As National Day Of Action Against Health Insurance Companies, California
Thousands to Gather in San Francisco and Around Country as 38,000 Insurance Industry Executives Meet for Annual AHIP ConventionNurses, Doctors, Patien...
• Fitch: Global Wireless Growth Slowing, But Still Strong in Many Developing Markets (Business Wire)
NEW YORK & LONDON----In Fitch Ratings' review of 72 operators from 27 different countries, total aggregate wireless subscribers reached 1.681 billion ...
• Human Genome Sciences shares fall on drug candidate swap (AP)
Shares of Human Genome Sciences fell Thursday after the biotechnology company bought back the rights to its cancer treatments, a move one analyst said...